| mRNA |
ABT-737 |
CTRPv2 |
pan-cancer |
AAC |
0.28 |
2e-14 |
| mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
0.26 |
5e-13 |
| mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.25 |
7e-12 |
| mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.24 |
1e-11 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
3e-11 |
| mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.23 |
9e-11 |
| mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.24 |
9e-11 |
| mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.23 |
3e-10 |
| mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
1e-09 |
| mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
4e-09 |